Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus FYREMADEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus FYREMADEL.
ASTRAMORPH PF vs FYREMADEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Category C
Category C
Opioid Analgesic
Opioid Analgesic